SOUTH SAN FRANCISCO, Calif., June 05, 2025--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, today announced the launch of its Single-Cell Genotype ...
("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of the ddSEQ™ Single-Cell 3' RNA-Seq Kit and ...
Latus Bio, a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), announced its launch and an initial closing of $54 million in Series A ...
Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular disease, and Synfini, Inc., an agile AI foundry for small-molecule drug discovery, today announced ...
The cell and gene therapy field is, some say, at a tipping point—poised to take off. The FDA has noted that, by next year, they aim to approve 10–20 new cell and gene therapies per year. To do that, ...
KAIST researchers have engineered a hybrid promoter that preserves its relative strength ranking across E. coli and yeast, ...
A Cambridge, Massachusetts biotechnology company dosed the first child in the world to receive an experimental gene therapy targeting GJB2 — the single most common genetic cause of childhood deafness ...
– Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Single-Cell Genotype and Targeted Gene Expression assay, expanding the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results